MOTS-c vs 5-Amino-1MQ: An Evidence Comparison

Verified against PubChem PUG-REST: CID 146675088 (MOTS-c), CID 950107 (5-Amino-1MQ cation), CID 66522933 (iodide salt). Formula, mass, IUPAC name and SMILES retrieved directly; the SMILES for CID 146675088 was read residue by residue and matches the 16-residue sequence MRWQEMGYIFYPRKLR. Fields marked “not verified” are ones we could not confirm against a primary chemical database — we leave them blank rather than guess.

Two molecules that share a research area and nothing else

The pairing of these two compounds is a product of subject-matter overlap, not chemical or mechanistic kinship. Both appear in published work on insulin sensitivity, adiposity and energy handling. Beyond that they have very little in common, and the two literatures do not cross-reference one another.

MOTS-c is a peptide. Lee and colleagues reported in Cell Metabolism in 2015 that a short open reading frame within the mitochondrial 12S rRNA gene encodes a 16-amino-acid peptide, which they named MOTS-c, for mitochondrial open reading frame of the twelve-S rRNA type-c (PMID 25738459). The same paper established its mitochondrial origin by depleting mitochondrial DNA in HeLa cells and showing loss of the transcript and of peptide immunoreactivity.

5-Amino-1MQ is a small-molecule enzyme inhibitor. It was developed as part of a methylquinolinium series targeting nicotinamide N-methyltransferase (NNMT), and was characterised by Neelakantan and colleagues in Biochemical Pharmacology (PMID 29155147). It is a quaternary organic cation, not a biologic.

The mass difference is close to fourteen-fold. PubChem lists MOTS-c at 2174.6 g/mol as the free peptide (CID 146675088) and the 5-Amino-1MQ cation at 159.21 g/mol (CID 950107), with the iodide salt at 286.11 g/mol (CID 66522933, CAS 42464-96-0). That difference is not trivia; it determines almost everything about how each has been formulated, administered and measured in the studies below.

What the MOTS-c literature reported

Lee and colleagues traced the cellular action of MOTS-c through unbiased metabolomic profiling in HEK293 cells, both stably overexpressing the peptide and treated with synthetic peptide. The metabolic signature pointed to the folate and methionine pathways and the de novo purine biosynthesis tethered to them. In overexpressing cells the intermediate AICAR accumulated to more than twenty-fold above control, with a corresponding fall in purines, and AMPK-alpha was phosphorylated at Thr172 in a time- and dose-dependent manner (PMID 25738459).

Importantly, the same paper reported that AMPK is only a partial mediator. Knockdown of AMPK-alpha2 alone reduced the glucose-stimulated glycolytic rate by 16 percent, knockdown of both alpha subunits by 30 percent, and the inhibitor compound C by 40 percent. Knockdown of SIRT1 produced a comparable 40 percent reduction. The pathway is therefore not a single clean switch, and the paper does not claim it is.

In vivo, the authors used intraperitoneal injection in mice. A seven-day course preceded hyperinsulinaemic-euglycaemic clamp studies in which the exogenous glucose infusion rate required to maintain euglycaemia rose by approximately 30 percent, with the effect localised to skeletal-muscle glucose disposal rather than hepatic glucose production. In outbred CD-1 mice on a 60 percent fat diet (N=10), 0.5 mg/kg/day prevented diet-induced weight gain and hyperinsulinaemia without any difference in caloric intake.

Kim and colleagues later reported that under glucose restriction MOTS-c translocates to the nucleus in an AMPK-dependent manner and associates with antioxidant-response-element genes and with NFE2L2/NRF2 (PMID 29983246).

What the 5-Amino-1MQ literature reported

The Neelakantan paper is the foundational characterisation, and its full text names 5-amino-1MQ explicitly as the lead compound taken into animals. In differentiated 3T3-L1 adipocytes, 24-hour treatment produced concentration-dependent suppression of the NNMT reaction product 1-methylnicotinamide, fitting a sigmoidal curve with an EC50 of 2.3 plus or minus 1.1 micromolar. Lipid accumulation during differentiation fell by 50 percent at 30 micromolar and 70 percent at 60 micromolar (PMID 29155147).

The selectivity data are unusually thorough and worth stating precisely. Across biochemical assays, 5-amino-1MQ did not inhibit DNMT1 or PRMT3 up to 600 micromolar, showed roughly 10 percent inhibition of COMT at 600 micromolar with no concentration-dependent trend, did not inhibit NAMPT up to 100 micromolar, and did not inhibit SIRT1 between 10 nanomolar and 300 micromolar.

One frequently repeated point deserves a correction. The claim that NNMT inhibition raised intracellular NAD+ in adipocytes is weaker in the source than in its retellings: the one-way ANOVA main effect on NAD+ was p=0.0568, described by the authors themselves as almost significant, with a post-test reaching significance only at the single 10 micromolar concentration. The SAM increase was firmer, significant at 30 micromolar.

The in vivo work was an 11-day subcutaneous study in male diet-induced obese C57BL/6 mice, nine per group, at 20 mg/kg three times daily. Independent groups have since used the compound: Dimet-Wiley and colleagues in a microbiome study (PMID 35013352), Yang and colleagues in bladder-cancer mouse models (PMID 39067875), and Akar and colleagues in HeLa cells (PMID 33645410).

Where the mechanisms actually diverge

The contrast is directional. In the reported literature MOTS-c behaves as a signalling peptide that switches an energy-sensing kinase pathway on: folate-pathway inhibition, AICAR accumulation, AMPK phosphorylation, and under stress a nuclear translocation that engages a transcriptional stress-response programme. Reviews summarising this body of work describe it as the folate-AICAR-AMPK axis (PMID 36670507, PMID 36761202).

5-Amino-1MQ works in the opposite direction. It switches a methyl-consuming enzyme off. NNMT transfers a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide and diverting nicotinamide away from the NAD+ salvage route. Inhibiting the enzyme was reported to lower 1-methylnicotinamide and raise SAM in cultured adipocytes.

The tissue contexts also differ. Lee and colleagues identified skeletal muscle as the primary target organ for MOTS-c, supported by clamp data localising the insulin-sensitivity effect to muscle glucose disposal. The Neelakantan work is centred on white adipose tissue, where NNMT expression and activity are reported to be highest.

The two therefore do not substitute for one another in any published experiment. No study retrieved for this page administered both, compared them head to head, or reported an interaction. Any claim that one is a version, analogue or oral equivalent of the other has no basis in the literature located here.

How far each has been taken toward humans

A ClinicalTrials.gov search across both compounds returned five records. Only one is an interventional trial administering either compound to people: NCT07505745, a Phase 2a randomised, double-blind, placebo-controlled study of MOTS-c in adults with prediabetes and overweight or obesity, sponsored by Hudson Biotech, with a planned enrolment of 120, subcutaneous administration, a 12-week treatment period and a Matsuda-index primary endpoint. It began in February 2026, is recruiting at a single site in Shenzhen, and has no posted data.

Registration is not evidence. The trial establishes that a sponsor has committed to testing the hypothesis; it says nothing about what will be found. Its primary completion date is February 2027.

One observational record, NCT04027712 from the University of Athens, tracked MOTS-c downregulation alongside platelet reactivity and amyloid in 120 patients with coronary artery disease and type 2 diabetes. Its registry status is listed as unknown.

For 5-Amino-1MQ the search returned nothing. There is no registered clinical trial of the compound in humans, in any phase, under any sponsor. The entire evidence base retrieved for it is cell culture and mouse.

This asymmetry is the single most consequential difference between the two entries, and it runs opposite to the direction implied by 5-Amino-1MQ being the more chemically conventional, more easily manufactured molecule.

What each body of evidence can and cannot address

The shape of each literature determines the questions it can answer, and neither is interchangeable with the other.

The MOTS-c literature is built around skeletal-muscle energy sensing, folate and purine metabolism, AMPK activation, and mitonuclear signalling. Its strongest quantitative work is mechanistic cell biology plus rodent physiology with clamp-based readouts. Its weakest area is human data, which at present consists of one recruiting trial and observational associations.

The 5-Amino-1MQ literature is built around NNMT enzymology, the S-adenosylmethionine methyl economy, and adipocyte lipogenesis. Its strongest quantitative work is biochemical: a defined EC50, an explicit selectivity panel across five off-target enzymes, and permeability measurements in PAMPA and Caco-2 assays. Its weakest area is translation of any kind, and a specific gap noted below concerns oral exposure.

Both compounds carry a further constraint on interpretation. The rodent studies used parenteral routes, intraperitoneal for MOTS-c and subcutaneous for 5-Amino-1MQ, and were short: seven days for the MOTS-c clamp work, eleven days for the 5-Amino-1MQ obesity study, three weeks for the longest MOTS-c high-fat-diet arm. Nothing in the retrieved literature speaks to exposure beyond those windows, to repeat administration, or to any population other than young adult male laboratory rodents.

What is not known

The gaps here are larger than the findings. Neither compound has a completed human trial with posted data. The rodent work for both used young adult male animals almost exclusively: Lee and colleagues used male CD-1 and C57BL/6 mice, Neelakantan and colleagues used 17-week-old male C57BL/6 mice. No female animals, no aged animals beyond a single 12-month comparison arm, and no non-rodent species appear in the primary studies retrieved. Exposure durations were short, from four days to three weeks, so nothing in this literature addresses what happens beyond that horizon. Both in vivo programmes used parenteral routes, so oral exposure is unmeasured for either compound. For 5-Amino-1MQ specifically, there is no pharmacokinetic profile in any species in the retrieved literature: no half-life, no distribution, no clearance data. For MOTS-c, the peptide's own pharmacokinetics after exogenous administration are similarly absent from the primary reports cited here. No study located compared the two compounds directly, and no study administered both. Off-target screening exists for 5-Amino-1MQ across five enzymes but was not extended to a broader panel; for MOTS-c no comparable selectivity screen was located at all.

Questions